CH713170B1 - Cosmetic or dermatological preparation containing an aqueous and a lipophilic fish extract. - Google Patents

Abstract

Cosmetic or dermatological preparation containing an aqueous and a lipophilic fish extract for the upholstery of the skin and / or for increasing the incorporation of triglycerides in adipocytes.

Description

Description: The present invention relates to a cosmetic or dermatological preparation comprising an aqueous and a lipophilic fish egg extract for plumping up the skin and / or for increasing the storage of triglycerides in adipocytes.

A known annoyance for many women and men is that the skin, especially the facial skin, loses volume and firmness with increasing age. As a result, the facial contours may change visibly. One result is undesirable wrinkling.

If one looks at the structure of human skin, the subcutis forms the deepest layer of skin. Depending on the body position, the subcutis has a different thickness. It is particularly thin on the forehead, while it is significantly thicker on the buttocks. Overall, the subcutis makes up 15 to 30% of body weight.

[0004] In general, the subcutaneous tissue is composed on the one hand of the connective tissue and on the other hand of fat cells. The latter serve as reserve cells to store excess nutrients that are not needed in the organism. In particular, fats such as triglycerides are stored. These reserve cells or fat cells are generally referred to as adipocytes. The formation of adipocytes occurs to a large extent in only three stages of human life: in the last three months of pregnancy, in the first year of birth and at the beginning of adolescence.

Scientific studies suggest that with increasing age the formation of the adipocytes decreases over the adipogenesis (see. Djian P, Roncari AK, Hollenberg CH 1983. Influence of anatomie site and âge on the réplication and différentiation of rat adipocyte precursors in culture J Clin Invest 72: 1200-1208; Kirkland JL, Hollenberg CH, Gillon WS 1990. Age, anatomie site, and the réplication and différentiation of adipocyte precursors. Am J Physiol 258: C206-C210; Schipper BM, Marra KG, Zhang W, Donnenberg AD, Rubin JP 2008. Regional anatomy and age effects on cell function of human adipose-derived stem cells. Ann Plastic Surg 60: 538-544; and Cartwright MJ, Schlauch K, Lenburg ME, Tchkonia T, Pirtskhalava T, Cartwright A, Thomou T, Kirkland JL 2010. Aging, depot origin, and preadipocyte gene expression. J Gerontol A Biol Sci Med Sei 65: 242-251). The decrease in dermal adipose tissue with age indicates that the adipocyte progenitor cells are lost or their activity is lost. The logical consequence here is the formation of wrinkles, since the firmness of the skin is reduced.

One ability of the adipocytes is the storage of triglycerides, which leads to the fact that skin layers can plump up. If many triglycerides are stored, the padded skin appears more relaxed. Depending on the region of the body, this is more or less desirable.

As already stated, the subcutaneous tissue on the face is characterized by a comparatively small layer thickness. A particularly effective storage of triglycerides can therefore lead to an effective cushioning of the skin in this area of the body. Such padding is advantageously accompanied by a visible reduction in the depth of the folds.

It is problematic, however, that only a small number of cosmetic active ingredients are known, which selectively lead to an increased incorporation of triglycerides. It is therefore desirable and therefore the object of the present invention to provide cosmetic preparations which cushion the skin particularly effectively and / or enable increased storage of triglycerides in adipocytes. In particular, the plumping effect should be measurable or visible after application of the cosmetic preparation on the facial skin.

These objects were surprisingly achieved by the subject matter of the present invention.

The object of the present invention is a cosmetic or dermatological preparation containing

I. an aqueous fish egg extract (I), characterized in that the aqueous fish egg extract (I) is obtainable by a1) suspending the fish eggs in an extraction mixture containing an oil phase and an aqueous phase, b1) homogenizing the suspension mixture a1) and c1) the aqueous phase of the homogenate b1) is extracted to obtain the aqueous fish extract (I);

and

II. A lipophilic fish egg extract (II), characterized in that the lipophilic fish egg extract (II) is obtainable by a2) suspending the fish eggs in an extraction mixture containing an oil phase and an aqueous phase, b2) homogenizing the suspension mixture a2) and c2) the oil phase of the homogenate b2) is extracted to obtain the lipophilic fish extract (II).

The aqueous phase obtained in point d) represents the aqueous fish egg extract (I) according to the invention.

The oil phase obtained in point c2) represents the lipophilic fish egg extract (II) according to the invention.

The present invention also relates to the cosmetic use of the cosmetic preparation according to the invention for plumping up the skin and / or for increasing the storage of triglycerides in adipocytes.

Unless otherwise stated, all the weight percentages (% by weight) listed below relate to the total weight of the cosmetic or dermatological preparation. If conditions are spoken of below, these relate to weight ratios, unless stated otherwise.

The expression “free of” means in the sense of the present disclosure that the proportion of the respective substance is less than 0.05% by weight. This ensures that introductions or contaminations with these substances are not included as “free from” according to the invention.

Unless otherwise stated, all tests and process steps were carried out under normal conditions. The term “normal conditions” means 20 ° C, 1013 hPa and a relative air humidity of 50%.

[0017] If the term skin is used below, this refers exclusively to human skin.

According to the present invention, a cosmetic or dermatological preparation containing an aqueous fish egg extract and a lipophilic fish egg extract is used in particular to plump up the facial skin and thus reduce the depth of wrinkles. Use of the specific cosmetic or dermatological preparation thus reduces the depth of the wrinkles that appear on the face with increasing age.

[0019] Document WO 2008 020 329 A2 describes the use of compositions which comprise differentiable cells, egg cell extracts or differentiable cellular extracts in order to prevent damage and functional disorders of cells or tissues and to promote cellular function. Furthermore, these compositions promote the appearance, vitality and health of cells and tissues. Specifically on page 89 in Example 11 it is described that an extract of salmon eggs can promote wound healing. However, neither the fish egg extracts according to the invention nor a specific effect with regard to the padding of the skin or the increased incorporation of triglycerides in adipocytes are described.

[0020] Document WO 2009 136 291 A2 also discloses production methods for extracts from fish eggs. The description of these methods is identical to that from WO 2008 020 329 A2. Example 13 discloses the preparation of an extract from salmon and trout eggs. As can be seen from Table 13, the composition of the extracts from the same fish species differs depending on the extraction method. The DNA and protein concentration contained varies significantly. It can therefore be assumed that depending on the extraction method, different effects can be achieved when using the extracts.

[0021] Furthermore, document WO 2011 138 687 A2 on page 28 discloses the same production method for extracts from fish eggs as in WO 2008 020 329 A2. The extraction from salmon eggs described in Example 5 is also based on the eggs being washed first. This is followed by suspension in an aqueous lysis buffer and homogenization. The manufacturing methods differ from the present invention.

No prior art document discloses an extraction process in which the fish eggs are suspended in an extraction mixture of an oil phase and an aqueous phase and homogenized therein. Thus, none of the aforementioned documents could lead the person skilled in the art to the subject of the present invention.

In general, it is possible according to the invention to produce the aqueous fish egg extract (I) and the lipophilic fish egg extract (II) in independent processes. This enables, for example, that an aqueous fish egg extract of sturgeon eggs according to the invention is contained in the preparation according to the invention together with a lipophilic fish egg extract of salmon eggs according to the invention. That is to say, if the expression “used both for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II)” is used in the disclosure below, this refers on the one hand to the individual, separate production processes of aqueous fish egg extracts according to the invention (I) or lipophilic fish egg extracts (II). On the other hand, the expression also relates to a production process according to the invention of the aqueous fish egg extract (I) and of the lipophilic fish egg extract (II) according to the invention, characterized in that the fish eggs are suspended in an extraction mixture containing an oil phase and an aqueous phase, which are obtained Suspension mixture is homogenized, and from this homogenate the aqueous phase is extracted to obtain the aqueous fish extract (I) and the oil phase of the homogenate is extracted to obtain the lipophilic fish extract (II). If it is stated below that, for example, certain fish eggs, process steps or parameters “are preferred or advantageous both for the production of the aqueous fish egg extract and for the production of the lipophilic fish egg extract”, this statement means that the selection of the fish eggs, process steps or parameters for the individual, independent production processes of the aqueous fish egg extract (I) or the lipophilic fish egg extract (II) are preferred, and that the selection of fish eggs, process steps or parameters for a production process of the aqueous fish egg extract and the lipophilic fish egg extract according to the invention are characterized in that the fish eggs are characterized in that an extraction mixture containing an oil phase and an aqueous phase, the suspension mixture obtained is homogenized, and from this homogenate the aqueous phase to obtain the aqueous fish egg Extract is extracted and the oil phase of the homogenate is extracted to obtain the lipophilic fish extract, preferred or advantageous.

If the aqueous and lipophilic fish egg extracts according to the invention, as described above, are produced together in a production process, this has the advantage that after the homogenization both the oil phase and the aqueous phase can be used to produce the extracts according to the invention. This is advantageous from an economic and ecological point of view, since fewer resources have to be used and waste products can be reduced.

Accordingly, a preferred object of the present invention is a cosmetic or dermatological preparation containing an aqueous fish egg extract and a lipophilic fish egg extract, characterized in that the aqueous fish egg extract (I) and the lipophilic fish egg extract (II) are obtainable by

a) the fish eggs are suspended in an extraction mixture containing an oil phase and an aqueous phase,

b) the suspension mixture a) is homogenized,

c) the aqueous phase of the homogenate b) is extracted to obtain the aqueous fish extract (I); and

d) the oil phase of the homogenate b) is extracted to obtain the lipophilic fish extract (II).

The aqueous phase obtained in point c) represents the aqueous fish egg extract (I) according to the invention. The oil phase obtained in point d) represents the lipophilic fish egg extract (II) according to the invention.

According to the invention, eggs of various fish species can be used both for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II). Preferred fish eggs for the production of the aqueous fish egg extract (I) and / or the lipophilic fish egg extract (II) are selected from the fish eggs of the salmon, trout and sturgeon. Particularly advantageous results are obtained in the production of the aqueous fish egg extract (I) and / or the lipophilic fish egg extract (II) when using sturgeon eggs. Accordingly, sturgeon eggs are preferably used both for the preparation of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II). A large number of different sturgeon genera are known, the eggs of which can in principle be used according to the invention in the production processes according to the invention. The Siberian sturgeon, the short-nosed sturgeon, the Yangtze sturgeon, sea sturgeon, the Russian sturgeon or Waxdick, the green sturgeon, the Sakhalin sturgeon, the Adriatic sturgeon, the Glattdick, the Atlantic sturgeon, among others, are known Persian sturgeon, the sterlet, the Amur sturgeon, the Chinese sturgeon, the Sternhausen, the European sturgeon, the white sturgeon, the Kaluga-Hausen and the European Hausen, which is often referred to as the Beluga sturgeon. It should be noted here that a large number of types of disturbance are threatened with extinction, so the use of these should be avoided. The most preferred according to the invention are the fish eggs of the white sturgeon (Acipenser transmontanus) and / or the Siberian sturgeon (Acipenser baerii) both for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II). According to the IUCN (International Union for Conservation of Nature and Natural Resources), the white sturgeon is not considered to be endangered.

In particularly advantageous embodiments of the invention, fish eggs from breeding sturgeon, in particular from bred Siberian and / or white sturgeon, are used exclusively. In this embodiment, it is furthermore extremely preferred if the fish eggs are obtained in a process which is not lethal for the fish.

It is advantageous according to the invention if the aqueous fish egg extract (I) and / or the lipophilic fish egg extract (II) are each produced within 24 hours after the fish eggs have been removed. It is also advantageous if the fish eggs are also preserved with borax after removal.

Alternatively, it is possible, although not preferred according to the invention, to freeze-dry the fish eggs after removal in a cryoprotectant and to store them at a storage temperature of 50 to -90 ° C. for up to 12 months. The cryoprotectant preferably consists of 1.5M 1,2-propanediol, 0.2M sucrose and water. Using the cryoprotectant prevents damage to the egg membrane during freezing and thawing. Freeze drying should advantageously be carried out at a rate of -1 ° C per minute to a storage temperature of -80 ° C. Thawing the eggs before making the fish egg extract should be done on ice until the fish eggs have reached a temperature of 1 ° C to 5 ° C. The aqueous fish egg extract (I) and / or the lipophilic fish egg extract (II) according to the invention is produced in this case after thawing the fish eggs to 1 ° C. to 5 ° C.

Both for the preparation of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II), the respective fish eggs are suspended in an extraction mixture containing an oil phase and an aqueous phase, so that a mixture of the fish eggs, the Oil phase and the aqueous phase is obtained. In both cases, this mixture is referred to as a suspension mixture.

According to the invention, the oil phase contained in the extraction mixture advantageously comprises at least one oil which is liquid at 20 ° C. both for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II). The oil Caprylic / Capric Triglyceride known under the INCI name has proven to be particularly preferred for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II), since these components are not to be expected in the fish eggs ,

It is also advantageous both for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II) if the proportion of the oil caprylic / capric triglycerides in the oil phase of the extraction mixture is at least 80% by weight, is preferably at least 90% by weight and particularly preferably at least 97% by weight, based on the total weight of the oil phase of the extraction mixture.

It is also advantageous both for the preparation of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II) if the oil phase contained in the extraction mixture contains at least one antioxidant. Tocopherol and / or BHT are preferably used as antioxidants both for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II), their total proportion in the oil phase of the extraction mixture being 0.1 to 0.5% by weight. %, based on the total weight of the oil phase of the extraction mixture. By using antioxidants within the oil phase of the extraction mixture, the components of the fish eggs are protected from oxidation during and after the homogenization of the fish eggs.

The aqueous phase contained in the extraction mixture for the production of the aqueous fish egg extract (I) and / or for the production of the lipophilic fish egg extract (II) according to the invention is advantageously a phosphate buffer, preferably containing 50 mM to 200 mM phosphates (for example from sodium hydrogen phosphate ) and 0.1 to 0.3 wt .-% EDTA, based on the total weight of the respective aqueous phase of the extraction mixture for the preparation of the aqueous fish extract (I) and / or for the production of the lipophilic fish extract (II). Furthermore, according to the invention, it is advantageous both for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II) if the aqueous phase of the extraction mixture according to the invention contains at least one preservative to prevent the growth of bacteria before, during and after the To prevent homogenization. Preservatives which are preferably used both for the preparation of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II) are selected from the group phenoxyethanol, phenethyl alcohol and / or ethylhexylglycerol. Advantageously according to the invention, both for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II), the total proportion of the preservatives, in particular the total proportion of the preservatives identified as preferred, in the aqueous phase of the extraction mixture is 0.5 to 3% by weight .-%, based on the total weight of the aqueous phase of the extraction mixture.

After the fish eggs have been suspended in the oil and water phase of the extraction mixture, a mixture of these three components is obtained which, according to the invention, is referred to as the suspension mixture both for the preparation of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II) , It is advantageous according to the invention both for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II) if the proportion by weight of the fish eggs in relation to the aqueous phase of the respective suspension mixture (a1) and or a2)) 1 : 2 to 2: 1, preferably 1: 1.2 to 1.2: 1. Furthermore, it is advantageous both for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II) if the proportion by weight of the fish eggs in relation to the oil phase of the respective suspension mixture (a1) and or a2)) is 1: 0, 2 to 1: 0.4.

According to the invention, both for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II) the fish eggs are homogenized in the above-described suspension mixture from the fish eggs themselves, the oil phase and the aqueous phase.

According to the invention, the term homogenization is understood to mean methods in which cells are destroyed in order to access their contents - organelles, proteins, DNA, RNA or other biomolecules.

In general, mechanical and non-mechanical digestion processes can be used both for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II) for the homogenization. Non-mechanical digestion processes correspond, for example, to chemical degradation of a cell wall. According to the invention, mechanical digestion methods are preferred both for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II). These include the dounce method, in which the cells are destroyed by shear forces, sonication with ultrasound, whereby the cells are sheared by cavitation forces, or digestions under the application of mechanical pressure, for example in which a sample is pressed under pressure through a narrow valve (Manton-Gaulin homogenizer). Since there may be different homogenizations depending on the homogenization processes, it is particularly preferred according to the invention to use homogenization processes while exerting mechanical pressure, the most preferred being processes using a Manton-Gaulin homogenizer or a French press.

Advantageously according to the invention, the extraction of the aqueous phase for the preparation of the aqueous fish egg extract (I) and the extraction of the oil phase for the production of the lipophilic fish egg extract (II) from the homogenates of the respective suspension mixture is carried out by centrifugation with subsequent phase separation. After the homogenization of the suspension mixture and subsequent centrifugation, an oil phase, an aqueous phase and a sediment are advantageously contained both for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II). In some cases, a further layer with cell components can be formed between the oil phase and the aqueous phase, which are suspended. In the subsequent separation and

Extraction of the aqueous phase of the homogenate should be avoided as far as possible to remove components from the suspended layer of cell components.

In centrifugation, it is advantageous both for the preparation of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II) if this is carried out at 1500 to 3000 G. The centrifugation time for the production of the aqueous fish egg extract (I) and for the production of the lipophilic fish egg extract (II) is advantageously 30 minutes to 2 hours. You should then wait until the phases have clearly separated. If the conditions marked as advantageous above are observed, a particularly clean separation of the components is possible.

The aqueous phase of the homogenate obtained already represents an aqueous fish egg extract (I) according to the invention. This contains a large number of different ingredients and can thus be defined specifically by the extraction method. Nevertheless, it has been shown that aqueous fish extracts (I) which are advantageous according to the invention are further characterized in that these DNA components in a weight fraction of 0.02 to 0.1% by weight, proteins in a weight fraction of 5 to 15% by weight. and carbohydrates in a proportion by weight of 0.5 to 1 wt .-%, based on the total weight of the aqueous fish egg extract (I).

For the purposes of the present disclosure, the term DNA constituents is understood to mean complete DNA strands and DNA hydrolyzates.

It was also surprisingly found that the process according to the invention for producing the aqueous fish egg extract (I) according to the invention is so gentle that vitamins B2, B5 and vitamin PP can additionally be extracted from the fish eggs. The use of other extraction methods known in the prior art, on the other hand, often leads to the loss or a considerable reduction of the vitamin components mentioned. Accordingly, cosmetic or dermatological preparations can now be provided which contain a particularly vitamin-rich aqueous fish egg extract (I).

For the purposes of the present invention, it is advantageous if the aqueous fish egg extract (I), obtained by the process according to the invention, in a total proportion of 0.0001 to 10% by weight, preferably 0.05 to 5% by weight and particularly preferably 0.1 to 2% by weight, based on the total weight of the cosmetic or dermatological preparation, is contained in the cosmetic or dermatological preparation.

Particularly advantageous embodiments of the invention are characterized in that the cosmetic or dermatological preparation contains an aqueous fish egg extract from sturgeon eggs, obtained by the process according to the invention, in a total proportion of 0.0001 to 10% by weight, preferably 0.05 to 5 % By weight and particularly preferably 0.1 to 2% by weight, based on the total weight of the cosmetic or dermatological preparation.

It has also surprisingly been found that the aqueous fish egg extract (I) obtained according to the invention can be stabilized by containing it with an aqueous glycine solution before incorporation into the cosmetic or dermatological preparation in a weight ratio of 1: 0.5 to 1: 1.5 1 to 2% by weight of glycine, based on the total weight of the aqueous glycine solution, is diluted. The weight ratio relates to the aqueous fish egg extract (I) in relation to the aqueous glycine solution. The use of the aqueous glycine solution stabilizes the proteins in the aqueous fish egg extract (I) obtained, so that its shelf life is increased.

Furthermore, it is advantageous if the aqueous glycine solution is additionally characterized in that it contains at least one emulsifier with an HLB value in the range from 8 to 12. The use of the emulsifier ensures that remaining oil-soluble ingredients, proteins and protein hydrolyzates within the aqueous fish extract (I) are stabilized, so that there is no deposition of substances on the surface of the aqueous extract (I) after prolonged storage. The weight fraction of this emulsifier in the aqueous glycine solution is preferably 0.5 to 2% by weight, based on the total weight of the aqueous glycine solution. Polysorbate 80 is particularly preferably chosen as the emulsifier.

Furthermore, it is advantageous if the aqueous glycine solution is additionally characterized in that it contains at least one preservative selected from the group consisting of ethylhexylglycerol, phenoxyethanol and / or phenethyl alcohol. The total weight fraction of the above-mentioned preservatives is particularly advantageously 0.5 to 3% by weight, based on the total weight of the glycine solution. Such glycine solutions according to the invention make it possible to dispense with heating for bacterial reduction of the aqueous fish egg extract (I) according to the invention. By using the glycine solution advantageous according to the invention, contamination of the aqueous fish egg extract (I) with bacteria is excluded or reduced.

Furthermore, the aqueous glycine solution is advantageously characterized in that it contains at least one electrolyte, preferably sodium chloride, in a total proportion of 0.5 to 2% by weight, based on the total weight of the glycine solution.

The solution obtained from the aqueous fish egg extract (I) and the aqueous glycine solution according to the invention advantageously has a pH in the range from 5.0 to 7.5, preferably 6.0 to 7.0, so that the contained Components cannot be degraded by too acidic or basic conditions.

In some cases it may also be advantageous to filter the product obtained from the aqueous fish egg extract (I) and the aqueous glycine solution, since solid or precipitated constituents contained in this way can be removed and a clear solution is obtained.

The product obtained from the aqueous fish egg extract (I) and the aqueous glycine solution can thus be stored without disadvantages for up to a year at 25 ° C. in the absence of light before incorporation into a cosmetic or dermatological preparation.

The aqueous fish egg extract (I) obtained can be incorporated either directly or advantageously after addition of the aqueous glycine solution described in a wide variety of cosmetic or dermatological preparations.

The oil phase of the homogenate obtained already represents the lipophilic fish egg extract (II) according to the invention. This contains a large number of different ingredients and can therefore be defined specifically via the starting substances and the extraction method. A component of the lipophilic fish egg extract (II) obtained according to the invention are fatty acids. It has been shown that it is advantageous in the sense of the present invention if a certain distribution of the different fatty acids is present. The weight fraction of monounsaturated fatty acids in the lipophilic fish egg extract (II) according to the invention is advantageously 30 to 50% by weight, in particular 35 to 45% by weight, based on the total weight of all fatty acids contained in the lipophilic fish egg extract (II). According to the invention, the fatty acids include all unbranched, saturated and unsaturated carboxylic acids containing 6 to 28 carbon atoms. It is also advantageous if the lipophilic fish egg extract (II) according to the invention is characterized in that the weight fraction of the polyunsaturated fatty acids in the lipophilic fish egg extract (II) contains 30 to 40% by weight, based on the total weight of all in the lipophilic fish egg extract (II) Fatty acids. Furthermore, it is also advantageous if the proportion by weight of the omega-3 fatty acids in the lipophilic fish egg extract (II) is 15 to 25% by weight, based on the total weight of all fatty acids contained in the lipophilic fish egg extract (II). In addition, advantageous lipophilic fish egg extracts (II) according to the invention are characterized in that the weight fraction of the omega-6 fatty acids in the lipophilic fish egg extract (II) is 10 to 20% by weight, based on the total weight of all fatty acids contained in the lipophilic fish egg extract (II).

It has also been shown that the stability, the shelf life and / or the purity of the lipophilic fish extract (II) according to the invention can be increased if the extracted oil phase of the homogenate is dried. Drying can advantageously be carried out using the salts suitable for this purpose, particularly advantageously using disodium sulfate (Na ₂ SO ₄ ).

Furthermore, it has also been found to be advantageous that the stability, the shelf life and / or the purity of the lipophilic fish egg extract (II) according to the invention can be increased by filtering the extracted oil phase. The filtration is advantageously carried out in such a way that the entire drying agent, for example disodium sulfate, is removed from the oil phase.

Furthermore, advantageous lipophilic fish egg extracts (II) according to the invention are characterized in that they contain at least one preservative selected from the group phenoxyethanol, phenethyl alcohol and ethylhexylglycerol.

The total proportion of preservatives, in particular the total proportion of preservatives selected from the group phenoxyethanol, phenethyl alcohol and ethylhexylglycerol, in the lipophilic fish egg extract (II) is advantageously from 0.1 to 3.5% by weight, based on the total weight of the lipophilic fish extract (II). If the above characteristics are observed, it has been shown that the lipophilic fish egg extract (II) has a shelf life against bacterial attack of at least 2 years. Accordingly, immediate incorporation into a cosmetic or dermatological preparation is no longer necessary.

In addition, the lipophilic fish egg extract (II) according to the invention is advantageously characterized in that the proportion by weight of triglycerides, in particular the proportion of decanoyl and octanoyl glycerides (caprylic / capric triglycerides), is 50 to 60% by weight, based on the total weight of the lipophilic fish egg extract (II).

For the purposes of the present invention, it is advantageous if the lipophilic fish egg extract (II) obtained by the process according to the invention is based on a total proportion of 0.001 to 10% by weight, preferably 0.02 to 5% by weight on the total weight of the cosmetic or dermatological preparation contained in the cosmetic or dermatological preparation according to the invention.

Particularly advantageous embodiments of the invention are characterized in that the cosmetic or dermatological preparation contains a lipophilic fish egg extract (II) from sturgeon eggs, obtained by the process according to the invention, in a total proportion of 0.001 to 10% by weight, preferably 0.02 to 5 wt .-%, based on the total weight of the cosmetic or dermatological preparation.

The cosmetic or dermatological preparations according to the invention can be in the usual cosmetic and / or dermatological galenical preparation forms, preferably as a gel, O / W emulsion, W / O emulsion, W / O / W emulsion, O / W / O -Emulsion, microemulsion, cosmetic stick are present.

The cosmetic or dermatological preparations according to the invention can be present, preferably as an emulsion, ointment, foundation, toner, aqueous solution, cream, gel, powder, mask, foam preparation and aerosol preparation.

Dermatological or cosmetic preparations that are applied to the facial skin for daily care are mostly formulated as emulsions. Emulsions are generally understood to mean heterogeneous systems which consist of two immiscible or only miscible liquids, one of the two liquids being dispersed in the form of very fine droplets in the other liquid. An emulsion appears homogeneous to the naked eye. If both liquids are water and oil and the oil is present as a finely divided droplet in the water, it is an oil-in-water emulsion (O / W emulsion). If, on the other hand, the water is present as a finely divided droplet in the oil, then it is a water-in-oil emulsion (W / O emulsion).

It is particularly advantageous according to the invention if the cosmetic or dermatological preparation in which the fish egg extracts according to the invention are present is in the form of an O / W emulsion.

[0067] Emulsifiers serve to stabilize emulsions. In this context, stabilizing means that the phase separation of the emulsion is prevented or delayed. Accordingly, stable emulsions can be produced by using appropriately selected emulsifier systems.

[0068] Emulsifiers are molecules with a polar, hydrophilic structural element and a non-polar, lipophilic structural element. In general, such molecules can be defined by the HLB value (dimensionless number between 0 and 20), which indicates whether there is a preferred water or oil solubility. Water-in-oil emulsifiers (W / O emulsifiers) usually have an HLB value in the range from 3 to 8. Accordingly, W / O emulsifiers promote the stabilization of an aqueous phase which is suspended in an oil phase. Oil-in-water emulsifiers (O / W emulsifiers) have an HLB value greater than 8 to 18. These promote the stabilization of an oil phase that is suspended in an aqueous phase.

If the cosmetic or dermatological preparation, which contains the aqueous fish egg extract and the lipophilic fish egg extract according to the invention, is in the form of an oil-in-water emulsion, it is advantageous if the cosmetic or dermatological preparation contains at least one O / W emulsifier contains an HLB value in the range of greater than 8 to 18. The O / W emulsifiers to be selected advantageously can be found, for example, in the following list:

HLB value Chemical name 8.2 triglycerol 8.3 Diethylenglycolmonolaurat 8.4 Polyoxyethylene (4) cetyl ether Polyoxyethylene glycol (400) dioleate 8.5 Natriumcaproyllactylat Polyethylene glycol (200) monostearate sorbitan 8.6 sorbitan Polyethylene glycol (200) monolaurate 8.8 Polyoxyethylene (4) myristyl ether Polyethylene glycol (400) dioleate 8.9 Nonylphenol, polyoxyethylated with 4 moles of EO 9.0 Oleth-5 9.2 to 9.7 Polyoxyethylene (4) lauryl alcohol 9.3 Polyoxyethylene (4) tridecyl alcohol 9.6 Polyoxyethylene (4) sorbitan monostearate 9.8 Polyethylenglycoi (200) monolaurate

HLB value Chemical name 10-11 Polyethylene glycol (400) monooleate 10.0 didodecyldimethylammonium 10.0 Polyethylene glycol (200) monolaurate Polyethylene glycol (400) dilaurate Polyethylene glycol (600) dioleate Polyoxyethylene (4) sorbitan monostearate Polyoxyethylene (5) sorbitan monooleate 10-12 Glyceryl stearate citrate 10.2 Polyoxyethylene (40) sorbitol hexaoleate 10.4 to 10.6 Polyoxyethylene glycol (600) distearate 10.5 Polyoxyethylene (20) sorbitan tristearate 10.6 sucrose monostearate 10.7 sucrose monooleate 11 to 11.4 Polyethylene glycol (400) monooleate 11.0 Polyethylene glycol (350) monostearate Polyethylene glycol (400) monotallate Polyoxyethylene (7) monostearate Polyoxyethylene glycol monooleate (8) Polyoxyethylene (20) sorbitan trioleate Polyoxyethylene (6) tridecyl alcohol 11.1 Polyethylene glycol (400) monostearate 11.2 Polyoxyethylene (9) monostearate sucrose monooleate sucrose monostearate 11.4 Polyoxyethylene (50) sorbitol hexaoleate Saccharosemonotallat Saccharosestearatpalmitat 11.6 Polyoxyethylene (400) monoricinoleate 11.7 Saccharosemonomyristat of sucrose 12.0 PEG-10 Soy Sterol triethanolamine 12.2 to 12.3 Nonylphenol, ethoxylated with 8 mol EO 12.2 Saccharosemonomyristat 12.4 saccharose

HLB value

12.5

12.7

12.8

12.9

13.0

13.0

13.1

13.2

13.3

13.5

13.7

13.9

14-16

14.0

14.2

14.3

14.4

14.5

14.8

14.9 to 15.2

15-15.9

15.0

Chemical name

Polyoxyethylene (10) oleyl alcohol, polyoxyethylene (10) oleyl ether polyoxyethylene (10) stearyl alcohol, polyoxyethylene (10) stearyl ether polyoxyethylene (10) stearyl cetyl ether

Polyoxyethylene (8) tridecyl alcohol

Polyoxyethylene glycol (400) monolaurate

Saccharosemonococoat

Polyoxyethylene (10) cetyl ether

Glycerol monostearate, ethoxylated (20 mol EO)

Eumulgin O 10 (polyoxyethylene (IO) oleyl ether)

Eumulgin 286 (Nonoxynol-10)

Eumulgin B 1 (Ceteareth-12)

C12 fatty amines, ethoxylated (5 mol EO)

Nonylphenol, ethoxylated (9.5 mol EO)

Polyethylene glycol (600) monostearate

tallôl polyoxyethylene (16)

Polyoxyethylene (4) sorbitan monolaurate

Nonylphenol, ethoxylated (10.5 mol EO)

Polyethylene glycol (600) monooleate

Polyoxyethylene (10) tridecyl alcohol

Polyethylene glycol (660) monotallate

Polyethylene glycol (1500) monostearate

Polyoxyethylene (1500) dioleate

Polyethylene glycol (400) monococoate

Polyoxyethylene (9) monolaurate

Castor oil, ethoxylated and hydrogenated with 40 EO

Polyoxyethylene (12) lauryl ether

Polyoxyethylene (12) tridecyl alcohol

stearyl polyoxyethylene (15)

stearylcetylether polyoxyethylene (15)

Mixture of C12-C15 fatty alcohols with 12 mol EO

Polyoxyethylene (12) lauryl alcohol

Polyoxyethylene glycol (600) monolaurate

Sorbitan monostearate, ethoxylated with 20 EO

Sorbitan monooleate, ethoxylated with 20 EO

PEG-20 Glyceryl Stéarate

HLB value Chemical name

PEG-40 Castor Oil

decyl glucoside

dodecyl

Dodecyltrimethylammonium chloride nonylphenol, ethoxylated with 15 mol EO polyethylene glycol (1000) monostearate polyoxyethylene (600) monooleate

15- 17 castor oil, ethoxylated with 60 EO and hydrogenated

15.3 C12 fatty amines, polyoxyethylated with 12 mol EO polyoxyethylene (20) oleyl alcohol, polyoxyethylene (20) oleyl ether

15.4 polyoxyethylene (20) stearyl cetyl ether

15.5 polyoxyethylene (20) stearyl alcohol

15.6 Polyoxyethylene glycol (1000) monostearate Polyoxyethylene (20) sorbitan monopalmitate

15.7 polyoxyethylene (20) cetyl ether

15.9 disodium triethanolamine distearylheptaglycol ether sulfosuccinate

16.0 nonylphenol ethoxylated with 20 mol EO

Polyoxyethylene (25) propylene glycol stearate

16-16.8 polyoxyethylene (30) monostearate

16.3-16.9 polyoxyethylene (40) monostearate

16.5-16.7 polyoxyethylene (20) sorbitan monolaurate

16.6 polyoxyethylene (20) sorbitol

16.7 C18 fatty amines, polyoxyethylated with 5 mol EO polyoxyethylene (23) lauryl alcohol

17.0 ceteareth-30, e.g. Eumulgin B 3

Octylglucoside (Triton CG 110)

Polyoxyethylene glyceryl monolaurate (30)

17.1 Nonylphenol, ethoxylated with 30 mol EO

17.4 polyoxyethylene (40) stearyl alcohol

18.8 PEG-100 Stéarate

Steareth-100

19.1 PEG-80 Sorbitan Laurate In the list above, the abbreviation EO stands for ethylene oxide.

Such an O / W emulsion can also advantageously contain W / O emulsifiers according to the invention, the ratio of the O / W emulsifiers to the W / O emulsifiers being chosen taking into account the respective HLB values such that sets an O / W emulsion. This is a known mixture of O / W emulsifiers and W / O emulsifiers

Commercial product Arlacel 170 from Croda containing glyceryl stearate and PEG-100 stearate, the ratio of the two substances being chosen so that a total HLB of about 11 results.

In addition to the aqueous fish egg extract and the lipophilic fish egg extract according to the invention, the cosmetic or dermatological preparation according to the invention advantageously contains oils selected from the group consisting of the lecithins and the fatty acid triglycerides, in particular the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids from 8 to 24, in particular 12 to 18, carbon atoms. The fatty acid triglycerides can advantageously be selected from the group of synthetic, semi-synthetic and natural oils, such as e.g. Olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, castor oil, wheat germ oil, grape seed oil, safflower oil, evening primrose oil, macadamia nut oil and the like.

Furthermore, the cosmetic or dermatological preparation according to the invention can advantageously contain oils which are selected from the group of branched and unbranched hydrocarbons and waxes, in particular petroleum jelly (petrolatum), paraffin oil, squalane and squalene, polyolefins and hydrogenated polyisobutenes. Among the polyolefins, polydecenes are the preferred substances.

Furthermore, the cosmetic or dermatological preparation according to the invention can advantageously contain fat and / or wax components from the group of vegetable waxes, animal waxes, mineral waxes and petrochemical waxes. Favorable according to the invention are candelilla wax, carnauba wax, Japanese wax, esparto grass wax, cork wax, guaruma wax, rice germ oil wax, sugar cane wax, berry wax, ouricury wax, montan wax, jojoba wax, shea butter, beeswax, shellac wax, walnut, lanolin (wool wax), buerzokerite fat, ceresin, earth wax Paraffin waxes and micro waxes.

Further advantageous fat and / or wax components are chemically modified waxes and synthetic waxes, such as those available under the trade names Syncrowax HRC (glyceryl tribehenate), and Syncrowax AW 1 C (C18-36 fatty acid) from CRODA GmbH and montan ester waxes , Sasol waxes, hydrogenated jojoba waxes, synthetic or modified beeswaxes (e.g. Dimethicon Copolyol beeswax and / or C30-50alkyl beeswax), polyalkylene waxes, polyethylene glycol waxes, but also chemically modified fats, such as hydrogenated vegetable oils (for example hydrogenated castor oil and / or hydrogenated coconut fat glycerides), triglycerides such as trihydroxystearin, fatty acids, fatty acid esters and glycol esters such as C20-40 alkyl stearate, C20-40 alkyl hydroxystearoyl stearate and / or glycol montanate.

It can also be advantageous for the purposes of the present invention if the cosmetic or dermatological preparation contains cyclic, branched and / or linear silicones. The group of cyclic, branched and / or linear silicones are also referred to as “silicone oils” in the context of the present disclosure. Linear silicone oils are described with the INCI name Dimethicone and have a structure according to the formula (I) (SiR ' ₃ ) - O —eSiR ^{2 2-0} (SiR ¹ 3) (I), while branched silicone oils according to the formula ( II)

R ²

I (SiR ¹ j) - O - (SiR ² , - Ο ~) χ · θί “~ θ —f SiR ² 2— Ο (SiR ¹ 3) (II) l

SiR ₂ - O (SiR ₃ ) can be described, where R ¹ and R ^{2 can} independently be a hydrogen atom, a methyl group or a linear or branched, saturated or unsaturated hydrocarbon group having 3 to 30 carbon atoms, and where x, y, and z are independently integer numbers in the range of 0 to 60,000. Cyclic silicones are known under the INCI name Cyclomethicone.

It is advantageous if the proportion by weight of the silicone oils in the cosmetic or dermatological preparation is 3% by weight to 10% by weight, based on the total weight of the cosmetic or dermatological preparation.

Furthermore, the cosmetic or dermatological preparation is advantageously characterized in that the total proportion of the oil phase in the O / W emulsion is 2 to 30% by weight, preferably 5% by weight to 25% by weight and particularly preferably 8 % By weight to 22% by weight, based on the total weight of the cosmetic or dermatological preparation, the lipophilic fish egg extract according to the invention being contained in the oil phase. The silicone oils also belong to the oil phase of the cosmetic or dermatological preparation.

Furthermore, it is advantageous if the total proportion of water in the cosmetic or dermatological preparation according to the invention is 50% by weight to 90% by weight, preferably 60% by weight to 80% by weight, based on the total weight the cosmetic or dermatological preparation.

It is also advantageous if the cosmetic or dermatological preparation contains one or more rheology modifiers. Preferred rheology modifiers are selected from the group of the following INCI substances:

Carbomer (Carbopole types 980, 981, 2984, 5984 from Lubrizol); Acrylates copolymer (e.g. Carbopol® Aqua SF-1 polymer from Lubrizol), Acrylates / C 10-30 alkyl acrylate crosspolymer (e.g. Pemulen TR 1, Pemulen TR 2, Carbopol 1328 from Lubrizol), hydroxyethyl acrylates / sodium Acryloyldimethyl Taurate Copolymer, Ammonium AcryloyldimethyltaurateA / P Copolymer (e.g. Aristoflex AVC from Clariant), Polyacrylate-1 Crosspolymer (e.g. Carbopol® Aqua CC Polymer from Lubrizol); Sodium polyacrylate (e.g. Cosmedia SP from BASF); Copolymer of vinyl pyrrolidone and acrylic acid

- celluloses and cellulose derivatives, e.g. Hydroxypropylmethyl cellulose, methyl cellulose, carboxymethyl cellulose, hydroxyethyl cellulose, hyaluronic acid and xanthan gum

- Starches, for example tapioca starch.

The rheology modifiers are particularly preferably selected from the group of substances known under the INCI name carbomer, acrylates / C 10-30 alkyl acrylate crosspolymer, sodium polyacrylates, hydroxyethyl acrylates / sodium acryloyldimethyl taurate copolymer and ammonium acryloyldimethyl taurate / VP copolymer.

The total proportion of these rheology modifiers, in particular the total proportion of the rheology modifiers identified above as preferred, is advantageously from 0.05 to 5% by weight, preferably from 0.1 to 2.5% by weight, based on the total weight of the cosmetic or dermatological preparation. In addition, it is particularly advantageous if, in addition to the substances mentioned above as being particularly preferred, tapioca starch is present in a proportion of up to 3.5% by weight, based on the total weight of the cosmetic or dermatological preparation.

Furthermore, it is advantageous if the weight ratio of all the rheology modifiers according to the invention to the oil phase contained is 1: 1 to 1:30, preferably 1: 2 to 1:28, particularly preferably 1:20 to 1:27. Such cosmetic or dermatological preparations according to the invention have a surprisingly advantageous creaminess and are not perceived by the consumer as crumbly or too oily and too liquid.

It is advantageous according to the invention if the cosmetic or dermatological preparation according to the invention contains cetyl alcohol, stearyl alcohol or a mixture of cetyl alcohol and stearyl alcohol.

If the cosmetic or dermatological preparation contains cetyl alcohol, stearyl alcohol or a mixture of cetyl alcohol and stearyl alcohol, it is advantageous according to the invention if the total proportion of these substances is from 0.5 to 5.5% by weight, based on the total weight of the cosmetic or dermatological preparation.

In addition, it is advantageous if the cosmetic or dermatological preparation according to the invention additionally selected one or more substances from the group consisting of ethanol, isopropanol, propylene glycol, propanediol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or contains monobutyl ether and / or diethylene glycol monomethyl or monoethyl ether. It is preferred if the cosmetic or dermatological preparation contains glycerol and / or propanediol.

It is also advantageous to use the cosmetic or dermatological preparations according to the invention as sunscreens. Accordingly, the preparations in the sense of the present invention preferably contain at least one UV-A, UV-B and / or broadband filter substance. The formulations may, although not necessary, optionally also contain one or more organic and / or inorganic pigments as UV filter substances, which may be present in the water and / or the oil phase.

The preparations according to the present invention can contain at least one UV filter substance which is liquid at room temperature.

Particularly advantageous UV filter substances which are liquid at room temperature for the purposes of the present invention are homomenthyl salicylate (INCI: homosalate), 2-ethylhexyl-2-cyano-3,3-diphenylacrylate (INCI: octocrylene), 2-ethylhexyl-2hydroxybenzoate (2 -Ethylhexylsalicylate, octylsalicylate, INCI: ethylhexyl salicylate) and esters of cinnamic acid, preferably 4-methoxycinnamic acid (2-ethylhexyl) ester (2-ethylhexyl-4-methoxycinnamate, INCI: ethylhexyl methoxycinnamate) and 4-methoxycinnamate (4-methoxycinnamate) : Isoamyl p-methoxycinnamate), 3- (4- (2,2-bis-ethoxycarbonylvinyl) -phenoxy) propenyl) methoxysiloxane / dimethylsiloxane copolymer which is available, for example, under the trade name Parsol® SLX from Hoffmann La Roche.

Preferred inorganic pigments are metal oxides and / or other metal compounds which are sparingly soluble or insoluble in water, in particular oxides of titanium (TiO ₂ ), zinc (ZnO), iron (for example Fe ₂ O ₃ ), zirconium (ZrO ₂ ), silicon ( SiO ₂ ), manganese (e.g. MnO), aluminum (Al ₂ O ₃ ), cerium (e.g. Ce ₂ O ₃ ), mixed oxides of the corresponding metals as well as mixtures of such oxides and the sulfate of barium (BaS04).

For the purposes of the present invention, the pigments can also advantageously be used in the form of commercially available oily or aqueous predispersions. Dispersing aids and / or solubilizing agents can advantageously be added to these predispersions.

According to the invention, the pigments can advantageously be surface-treated ("coated"), with a hydrophilic, amphiphilic or hydrophobic character, for example, being formed or retained. This surface treatment can consist in that the pigments are provided with a thin hydrophilic and / or hydrophobic inorganic and / or organic layer by methods known per se. For the purposes of the present invention, the various surface coatings can also contain water.

Suitable titanium dioxide particles and predispersions of titanium dioxide particles are available under the following trade names from the companies listed:

trade name coating Manufacturer MT-100TV Aluminum hydroxide / stearic acid Tayca Corporation MT-100Z Aluminum hydroxide / stearic acid Tayca Corporation Eusolex T-2000 Alumina / Simethicone Merck KgaA Titanium dioxide T805 (Uvinul TiO ₂ ) octyltrimethylsilane Degussa Tioveil AQ 10PG Alumina / Silica Solaveil / Uniqema Eusolex T-aqua Water / alumina / sodium metaphosphate Merck

Advantageous UV-A filter substances in the sense of the present invention are dibenzoylmethane derivatives, in particular the 4- (tert-butyl) -4'-methoxydibenzoylmethane (CAS No. 70356-09-1), which is sold by Givaudan under the brand name Parsol® 1789 and is sold by Merck under the trade name Eusolex® 9020.

Advantageous UV filter substances for the purposes of the present invention are also:

• Phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid and its salts, especially the corresponding sodium, potassium or triethanolammonium salts, especially the phenylene-1,4 -bis- (2benzimidazyl) -3,3'-5,5'-tetrasulfonic acid bis-sodium salt with the INCI name Disodium Phenyl Dibenzimidazol Tetrasulfonate (CAS No .: 180898-37-7), which, for example, under the trade name Neo Heliopan AP is available from Symrise;

• Salts of 2-phenylbenzimidazole-5-sulfonic acid, such as its sodium, potassium or triethanolammonium salt and the sulfonic acid itself with the INCI name phenylbenzimidazole sulfonic acid (CAS No. 27503-81-7), which is sold, for example, under the trade name Eusolex 232 is available from Merck or from Neo Heliopan Hydro from Symrise;

1,4-di (2-oxo-10-sulfo-3-bornylidenemethyl) benzene (also: 3,3 '- (1,4-phenylenedimethylene) -bis- (7,7-dimethyl-2-oxo- bicyclo- [2.2.1] hept-1-ylmethane sulfonic acid) and its salts (especially the corresponding 10-sulfato compounds, especially the corresponding sodium, potassium or triethanolammonium salt), which is also called benzene-1,4- di (2-oxo-3-bornylidenemethyl-10-sulfonic acid) Benzene-1,4-di (2-oxo-3-bornylidenemethyl-10-sulfonic acid) has the INCI name Terephtaildene Dicampher Sulfonic Acid (CAS no .: 90457-82-2) and is available, for example, under the trade name Mexoryl SX from Chimex;

Sulfonic acid derivatives of 3-benzylidene camphor, e.g. 4- (2-oxo-3-bornylidene methyl) benzenesulfonic acid, 2-methyl-5- (2-oxo-3-bornylidene methyl) sulfonic acid and their salts.

• benzoxazole derivatives, such as e.g. 2,4-bis- [5-1 (dimethylpropyl) benzoxazol-2-yl- (4-phenyl) imino] -6- (2ethylhexyl) imino-1,3,5-triazine with CAS No. 288254 -16-0, which is available from 3V Sigma under the trade name Uvasorb® K2A.

Hydroxybenzophenones, e.g. the 2- (4'-diethylamino-2'-hydoxybenzoyl) benzoic acid hexyl ester (also: aminobenzophenone), which is available under the trade name Uvinul A Plus from BASF.

Triazine derivatives, e.g. 2,4-bis - {[4- (2-ethyl-hexyloxy) -2-hydroxy] phenyl} -6- (4-methoxyphenyl) -1,3,5-triazine (INCI: bis-ethylhexyloxyphenol methoxyphenyl triazine), which is available from CIBA-Chemicals GmbH under the trade name Tinosorb®S; Dioctylbutylamidotriazon (INCI: Diethylhexyl Butamido Triazone), which is available under the trade name UVASORB HEB from Sigma 3V; 4,4 ', 4- (1,3,5-triazine-2,4,6-triyltriimino) tris-benzoic acid tris (2-ethylhexyl ester), also: 2,4,6-tris [anilino- (p -carbo-2'-ethyl-1'-hexyloxy)] - 1,3,5-triazine (INCI: Ethylhexyl Triazone), which is from BASF

Aktiengesellschaft is marketed under the trade name UVINUL® T 150; 2- [4,6-bis (2,4-dimethylphenyl) -1,3,5-triazin-2-yl] -5- (octyloxy) phenol (CAS No .: 2725-22-6).

Benzotriazoles, e.g. 2,2'-methylene-bis- (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) phenol) (INCI: Methylene Bis-Benztriazolyl Tetramethylbutylphenol), e.g. is available under the trade name Tinosorb® M from CIBA-Chemicals GmbH.

• 3-benzylidene camphor derivatives, preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;

• 4-aminobenzoic acid derivatives, preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4 (dimethylamino) benzoic acid amyl ester;

• esters of benzalmaionic acid, preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester;

Esters of cinnamic acid, preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;

• derivatives of benzophenone, preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone and • UV filters bound to polymers • ethylhexyl-2-cyano- 3,3-diphenyl acrylate (octocrylene), which is available from BASF under the name Uvinul® N 539 T.

Particularly advantageous cosmetic or dermatological preparations in the sense of the present invention, which are distinguished by a high or very high UV-A protection, preferably contain, in addition to the filter substance (s) according to the invention, further UV-A and / or broadband filters, in particular dibenzoyl methane derivatives [for example the 4- (tert-butyl) -4'-methoxydibenzoylmethane] and / or the 2,4-bis - {[4- (2-ethylhexyloxy) -2-hydroxy] phenyl } -6- (4-methoxyphenyl) -1,3,5-triazine and / or phenylene-1,4-bis- (2-benzimidazyl) -3,3'5,5'-tetrasulfonic acid bis-sodium salt each individually or in any combination with each other.

The list of UV filters mentioned, which can be used in the sense of the present invention, should of course not be limiting.

The total amount of the filter substances is in the range from 0.1 to 30% by weight, preferably 0.5 to 10% by weight, in particular 1.0 to 8.0% by weight, in each case based on the Total weight of the cosmetic or dermatological preparations - chosen to provide cosmetic or dermatological preparations that protect the hair or skin from the entire range of ultraviolet radiation.

It is also advantageous if the cosmetic or dermatological preparation according to the invention contains at least one active ingredient for cosmetic treatment and / or cosmetic prophylaxis of undesired skin pigmentation. Accordingly, the cosmetic or dermatological preparation advantageously contains at least one alkyl amide thiazole.

Advantageous alkylamidothiazoles for the purposes of the present invention are substances of the general formula

R ⁴ in which R ³ , R ⁴ , X 'and Y' are different, in some cases identical or completely identical and can mean independently of one another:

R ³ = -Ci-C24-alkyl (linear and branched), -Ci-C24-alkenyl (linear and branched), -Ci-C ₈ -cycloalkyl, -Ci-C ₈ -cycloalkyl-alkylhydroxy, -Ci -C ₂₄ alkylhydroxy (linear and branched), -Ci-C ₂₄ alkylamine (linear and branched), -Ci-C ₂₄ alkylaryl (linear and branched), -Ci-C ₂₄ alkylaryl alkyl hydroxy (linear and branched) , -Ci-C ₂₄ alkyl heteroaryl (linear and branched), -Ci-C ₂ 4-alkyl-O-Ci-C ₂₄ alkyl (linear and branched), -Ci-C ₂₄ alky-morpholino, -Ci-C ₂₄ alky-piperidino, -Ci-C ₂₄ alky-piperazino, -Ci-C ₂ 4 alky-piperazino-N-alkyl means, R ⁴ = H, -C-ι — C ₂ 4-alkyl (linear and branched), -C- | -C ₂₄ alkenyl (linear and branched), -C- | -C ₈ cycloalkyl, -C- | -C ₂₄ -hydroxyalkyl (linear and branched), -C-ι — C ₂₄ -Alkylaryl (linear and branched), -C- | -C ₂₄ -alkylheteroaryl (linear and branched), means, X '= -H, -C-ι-C ₂₄ -alkyl (linear and branched), - Ci-C ₂₄ alkenyl (linear and branched), -Ci-C ₈ -cycloalkyl, -Ci-C ₂₄ aryl (if necessary, simple o the multiple substituted with -OH, -F, -Cl, -Br, -I, -OMe, -NH ₂ , -CN), -Ci-C ₂₄ heteroaryl (optionally, single or multiple substituted with -OH, -F , -Cl, -Br, -I, -OMe, -NH ₂ , -CN), -C- | -C ₂₄ alkylaryl (linear and branched), -C- | -C ₂₄ alkyl heteroaryl (linear and branched) , -Aryl (optionally, mono- or polysubstituted with -OH, -F, -Cl, -Br, -I, -OMe, -NH ₂ , -CN), -phenyl, -2,4-dihydroxyphenyl, -2, 3-dihydroxyphenyl, -2,4-dimethoxyphenyl, -2,3-dimethoxyphenyl means, Y '= H, -C-ι-C ₂₄ -alkyl (linear and branched), -Ci-C ₂₄ -alkenyl ( linear and branched), -Ci-C ₈ -cycloalkyl, -Ci-C ₂₄ aryl, -C- | -C ₂₄ -heteroaryl, -C-ι — C ₂₄ -alkylaryl (linear and branched), -C- | - C ₂₄ alkyl heteroaryl (linear and branched), aryl, phenyl, -2,4-dihydroxyphenyl, -2,3dihydroxyphenyl, -2,4-dimethoxyphenyl, -2,3-dimethoxyphenyl, -COO-alkyl, -COO- Alkenyl, -COO-cycloalkyl, -COO-aryl, -COO-heteroaryl means, [0106] and X ', Y' can optionally also mean = condensed aromatic , Where X 'and Y' can form aromatic or aliphatic homo- or heterocyclic ring systems with up to n ring-forming atoms, and the number n can take on values from 5 to 8, and the respective ring systems in turn with up to n - 1 Alkyl groups, hydroxyl groups, carboxyl groups, amino groups, nitrile functions, sulfur-containing substituents, ester groups and / or ether groups can be substituted.

The thiazoles mentioned can exist both as a free base and as a salt: e.g. as fluoride, chloride, bromide, iodide, sulfate, carbonate, ascorbate, acetate or phosphate. In particular as halogen salts, such as Chloride and bromide.

X 'is advantageously selected from the group of the substituted phenyls, it being possible for the substituents Z' to be selected from the group -H, -OH, -F, -Cl, -Br, -I, -OMe, -NH ₂ , -CN, acetyl and may be the same or different.

HO

, 3 X 'is particularly advantageously selected from the group of phenyl groups substituted by one or more hydroxyl groups, the substituent Z' being able to be selected from the group -H, -OH, -F, -Cl, -Br, - I, -OMe, -NH ₂ , -CN, acetyl and the following generic structure is preferred, in which Y ', R ³ and R ⁴ can have the properties defined above.

HO.

O those compounds in which X =

HO.

Y '= H R ³ = -Ci-C ₂ 4 -alkyl (linear and branched), -Ci-C ₂₄ alkenyl (linear and branched), -Ci-C ₈ -cycloalkyl, -C- | - C ₈ -cycloalkyl-alkylhydroxy, -C- | -C ₂₄ alkylhydroxy (linear and branched), -C- | -C ₂₄ alkylamine (linear and branched), -C- | -C ₂₄ alkylaryl (linear and branched), - Ci-C ₂₄ -alkyl-aryl-alkyl-hydroxy (linear and branched), -Ci-C ₂₄ -alkylheteroaryl (linear and branched), -Ci-C ₂₄ -alkyl-O-Ci-C ₂₄ -alkyl (linear and branched), -CiC ₂₄ alky-morpholino, -CiC ₂₄ alky-piperidino, -Ci-C ₂₄ alky-piperazino, -CiC ₂₄ alky-piperazino-N-alkyl means, [0113] R ⁴ = H, -Ci-C ₂₄ alkyl (linear and branched).

[0114] Z '= -H, -OH, -F, -Cl, -Br, -I, -OMe, -NH ₂ , -CN, acetyl.

Compounds in which are particularly preferred

X =

HO.

-OH

Y = H R ³ = -Ci-C ₂₄ alkyl (linear and branched), -Ci-C ₂₄ alkenyl (linear and branched), -Ci-C ₈ cycloalkyl, -CiC ₈ cycloalkyl alkylhydroxy , -C- | -C ₂₄ alkylhydroxy (linear and branched), -C- | -C ₂₄ alkylamine (linear and branched), -C- | -C ₂₄ alkylaryl (linear and branched), -Ci-C ₂₄ alkylaryl -Alkyl-hydroxy (linear and branched), -Ci-C ₂₄ -alkyl heteroaryl (linear and branched), -Ci-C ₂₄ -alkyl-O-Ci-C ₂₄ -alkyl (linear and branched), -C- | - C ₂₄ alky-morpholino, -C- | -C ₂₄ alky-piperidino, -Ci-C ₂₄ alky-piperazino, -CiC ₂₄ alky-piperazino-N-alkyl means, [0117] R ⁴ = H.

The compounds [0119]

HO.

.OH

S

H

7 / - (4- (2,4-dihydroxyphenyl) thiazol-2-yl) pivalamide

// - (4- (2,4-dihydroxyphenyl) thiazol-2-yl) Isobutyramide

// - (4- (2,4-dihydroxyphenyl) thiazol-2-yl) butyramides

// - (4- (2,4-dihydroxyphenyl) thiazol-2-yl) heptanamide

// - (4- (2,4-dihydroxyphenyl) thiazol-2-yl) -6-fiydroxyhexanarnide

// - (4- (2,4-dihydroxyphenyl) thiazol-2-yl) -3-hydroxypropanamides and

.V- (4- (2,4-düiydroxyphenyl) Îhiazo! -2-YLJ-2-methoxyacetaraide

3-amino -? / - (4- (2,4-dihydroxyphenyl) £ -thiazol-2-yl) propanamides

// - (4- (2,4-dihydroxyphenyl) thiazol-2-yl) -4- (hydroxymethyl) cycIohexanecarboxamide

// - (4 (2,4-dihydroxyphenyl) thiazol-2-yl) cyclohexanecarboxamide

7V- (4- (2,4-dihydroxyphenyl) thia2ol-2-yl) -2- (4- (hydroxymethyl) phenyl) acetainides are the preferred according to the invention.

Advantageously according to the invention, the proportion of the alkylamidothiazoles described above in the cosmetic or dermatological preparations according to the invention is 0.000001 to 10% by weight, in particular 0.0001 to 3% by weight, very particularly 0.001 to 1% by weight, each based on the total weight of the dermatological or cosmetic preparations.

Accordingly, the cosmetic or dermatological preparations can also contain further cosmetic auxiliaries, as are usually used in such preparations, for example other consistency agents, film formers, stabilizers, fillers, preservatives, perfumes, substances for preventing foaming, dyes, other pigments, which have a coloring effect, surface-active substances, softening, moisturizing and / or moisturizing substances, anti-inflammatory substances, additional active substances such as vitamins or proteins, insect repellents, bactericides, virucides, salts, antimicrobial, proteolytic or keratolytically active substances or other common components of a cosmetic formulation such as further alcohols, polyols, foam stabilizers, organic solvents or electrolytes.

Examples The following examples are intended to illustrate the present invention without restricting it. Unless otherwise stated, all quantities, parts and percentages are based on the weight and the total amount or on the total weight of the preparations.

(a) Production of an aqueous fish egg extract (I) from white sturgeon To produce a fish egg extract according to the invention, fish eggs from white sturgeon (fish eggs from breeding stocks were used exclusively) were added and borax was added. The aqueous fish egg extract was produced within 24 hours after removal.

An oil phase was also provided, consisting of 99.98% by weight of caprylic / capric triglycerides, 0.01% by weight of tocopherol and 0.01% by weight of BHT.

The additional aqueous phase provided consisted of:

100 mM phosphates (from sodium hydrogen phosphate);

% By weight phenoxyethanol;

% By weight of the commercial product Sensivia Pa 20 from Schülke & Mayr, containing phenethyl alcohol and ethylhexylglycerol;

0.2% by weight EDTA; and

Water.

The oil phase provided and the aqueous phase provided were combined and the fish eggs were then suspended in this mixture. The weight ratio of the oil phase to the fish eggs was 0.3: 1 and the weight ratio of the aqueous phase to the fish eggs was 1: 1.

The mixture obtained from the oil phase, the aqueous phase and the fish eggs was then homogenized by using a Manton-Gaulin homogenizer.

The homogenate obtained was then centrifuged at 2000 G for one hour. A manual phase separation then took place, the water phase representing the aqueous fish egg extract (I) according to the invention.

To improve the shelf life of the aqueous fish egg extract (I) obtained, this was in a ratio of 1: 1 with an aqueous glycine solution consist of 1.5 wt .-% glycine, 1.5 wt .-% sodium chloride, 1.5 wt. -% phenoxyethanol, 1.0 wt .-% polysorbate 80 and water mixed. Filtration was then carried out to improve the purity.

The mixture obtained from aqueous fish egg extract (II) and glycine solution is referred to in the following example recipes as aqueous fish egg extract solution from (a).

(b) Production of a Lipophilic Fish Egg Extract from White Sturgeon To produce a fish egg extract according to the invention, fish eggs from white sturgeon (fish eggs from breeding stocks were used exclusively) were taken and mixed with borax. The lipophilic fish egg extract was produced within 24 hours after removal.

In addition, an oil phase was provided, consisting of 99.98% by weight of caprylic / capric triglycerides, 0.01% by weight of tocopherol and 0.01% by weight of BHT.

[0133] The additionally provided aqueous phase consisted of:

100 mM phosphates (from sodium hydrogen phosphate);

% By weight phenoxyethanol;

% By weight of the commercial product Sensivia Pa 20 from Schülke & Mayr, containing phenetyl alcohol and ethylhexylglycerol;

0.2% by weight EDTA; and

Water.

The oil phase provided and the aqueous phase provided were combined and the fish eggs were then suspended in this mixture. The weight ratio of the oil phase to the fish eggs was 0.3: 1 and the weight ratio of the aqueous phase to the fish eggs was 1: 1.

The mixture obtained from the oil phase, the aqueous phase and the fish eggs was then homogenized by using a Manton-Gaulin homogenizer.

The homogenate obtained was then centrifuged at 2000 G for one hour. This was followed by manual phase separation, the oil phase representing the lipophilic fish egg extract (II) according to the invention.

To improve the shelf life of the lipophilic fish egg extract (II) obtained, it was dried with sodium sulfate and then filtered to improve the purity in order to remove the sodium sulfate and other insoluble constituents.

(c) Analysis of the aqueous fish egg extract (I) from white sturgeon from (a) The analysis of the water phase of the homogenate from (a), that is to say the aqueous fish egg extract (I) according to the invention before the addition of the glycine solution, has determined the following components of the extract can:

• Proteins = 9% by weight • DNA = 0.6% by weight • Carbohydrates = 0.84% by weight • Vitamin B2 (riboflavin) = 376 pg / 100g • Vitamin B5 (pantothenic acid) = 2.40 mg / 100g • Vitamin PP (niacin / amide) = 6.12 mg / 100g, the percentages by weight relating to the total weight of the water phase of the homogenate from (a), ie the aqueous fish egg extract (l).

(d) Analysis of the lipophilic fish egg extract (II) from white sturgeon from (b) The analysis of the oil phase of the homogenate from (b), that is to say the lipophilic fish egg extract (II) according to the invention, showed that the proportion of saturated fatty acids in the lipophilic fish egg extract 23.1% by weight, based on the total weight of all fatty acids contained.

In addition, it was found that the proportion of monounsaturated fatty acids in the lipophilic fish egg extract (II) is 41.7% by weight, based on the total weight of all fatty acids contained.

In addition, it was found that the proportion of polyunsaturated fatty acids in the lipophilic fish egg extract (II) is 35.2% by weight, based on the total weight of all fatty acids contained.

In addition, it was found that the proportion of omega-3 fatty acids in the lipophilic fish egg extract (II) is 20.3% by weight, based on the total weight of all the fatty acids contained.

In addition, it was found that the proportion of omega-6 fatty acids in the lipophilic fish egg extract (II) is 14.8% by weight, based on the total weight of all the fatty acids contained.

The proportion of phenoxyethanol is in the range of 0.1 to 1.5 wt .-% based on the total weight of the lipophilic fish extract (II).

(e) Production of an aqueous and a lipophilic fish egg extract in a process from eggs of the Siberian sturgeon. To produce an aqueous fish egg extract (I) and a lipophilic fish egg extract (II) in a process, fish eggs were from the Siberian sturgeon (fish eggs were used exclusively taken from breeding stock) and mixed with borax. The aqueous fish egg extract (I) and the lipophilic fish egg extract (II) were produced within 24 hours after removal.

In addition, an oil phase was provided, consisting of 99.98% by weight of caprylic / capric triglycerides, 0.01% by weight of tocopherol and 0.01% by weight of BHT.

The additional aqueous phase provided consisted of:

100 mM phosphates (from sodium hydrogen phosphate);

% By weight phenoxyethanol;

% By weight of the commercial product Sensivia Pa 20 from Schülke & Mayr, containing phenetyl alcohol and ethylhexylglycerol;

0.2% by weight EDTA; and

Water.

The oil phase provided and the aqueous phase provided were combined and the fish eggs were then suspended in this mixture. The weight ratio of the oil phase to the fish eggs was 0.3: 1 and the weight ratio of the aqueous phase to the fish eggs was 1: 1.

The mixture obtained from the oil phase, the aqueous phase and the fish eggs was then homogenized by using a Manton-Gaulin homogenizer.

The homogenate obtained was then centrifuged at 2000 G for one hour. This was followed by manual phase separation, the water phase representing the aqueous fish egg extract (I) according to the invention and the oil phase representing the lipophilic fish egg extract (II) according to the invention.

To improve the shelf life of the aqueous fish extract (I) obtained, this was in the ratio 1: 1 with an aqueous glycine solution consisting of 1.5 wt .-% glycine, 1.5 wt .-% sodium chloride, 1.5 wt. -% phenoxyethanol, 1.0 wt .-% polysorbate 80 and water mixed. Filtration was then carried out to improve the purity.

The mixture of aqueous fish egg extract and glycine solution obtained is referred to in the following example recipes as aqueous fish egg extract solution from (e).

To improve the shelf life of the lipophilic fish egg extract (II) obtained, it was dried with sodium sulfate and then filtered to improve the purity in order to remove the sodium sulfate and other insoluble constituents.

Example recipes:

[0155]

Example number

PEG-100 stearate PEG-20 glyceryl stearate PEG-40 stearate

Ceteareth-25

Steareth-100

Ceteth-20 Myristyl Myristate Glyceryl Stearate Stearyl Alcohol Cetearyl Alcohol Cetyl Alcohol

Hydrogenated Coco Glycerides Butyrospermum Parkii (Shea) Butter C12-15 Alkyl Benzoate Butylene Glycol Dicaprylate / Dicaprate

1 2 3 4 5 2.0 0.9 1.1 0.5 1.0 0.5 2.0 1.0 1.0 1.0 1.1 2.0 2.0 1.0 4.0 2.5 1.0 3.0 2.0 2.0 2.0 3.0 2.0 3.5 1.0 1.5

Caprylic / Capric triglycerides 1.0 1.0 2.0 2.0 Ethylhexyl cocoate 3.0 1.5 octyldodecanol 1.0 Paraffinum Liquidum 1.0 Cera Microcristallina 2.0 1.0 1.5 Cyclometh icone 4.1 1.0 4.0 3.5 5.0 Dimethicone 2.3 1.0 1.2 Dicaprylyl ether 1.0 4.0 2.0 Dicarprylyl carbonates 2.8 N- (4- (2,4-dihydroxyphenyl) thiazol-2-yl) -isobutyramide 0.2 0.1 0.05 0.3 0.4 Ethylhexyl methoxycinnamate 4.0 3.0 5.0 2.0 2.5 Disodium Phenyl Dibenzimidazole Tetrasulfonate 1.0 1.0 1.5 0.5 2.0 Phenylbenzimidazole Sulphonic Acid 2.0 3.0 1.0 1.5 1.5 Ethylhexyl triazone 2.0 octocrylene 2.5 Ethylhexyl salicylate 1.0 Ubiquinone (G10) 0.05 aqueous fish egg extract solution from (a). (50% aqueous fish egg extract (I) + 50% glycine solution) 0.4 0.2 0.16 0.4 0.1 Lipophilic fish egg extract after working up from (b) 0.2 0.1 0.1 0.3 0.05 biotin 0.04 Retinyl palmitate 0.1 Thioctic acid 0.1 Tocopheryl Acetate 1.0 Sodium citrate 0.1 Sodium ascorbyl phosphate 0.1 0.1 Trisodiurn EDTA 0.1 phenoxyethanol 0.4 0.4 0.4 0.4 Butylparaben 0.6 0.3 0.2 0.3 0.3 Alcohol Denat. 2.0 Xanthan gum 0.1 Carbomer 0.05 0.1 0.1 polyacrylamides 0.2 glycerin 10 6.0 6.5 7.5 8.0 Butylene glycol 2.0 1.0 Fillers / additives (distarch phosphate, SiO ₂ , BHT, talc, 0.1 1.0 0.2 0.5 0.05

aluminum stearate)

perfumes q.s. q.s. q.s. q.s. q.s. Aqua ad ad ad ad ad 100 100 100 100 100

Example number 6 7 8th 9 10 PEG-50 stéarate 2.5 1.0 PEG-40 Stéarate 1.0 1.0 0.5 PEG-8 stéarate 1.0 PEG-8 Distearate 1.0 Glyceryl stéate 3.0 Sorbitan Stéarate 1.0 Steareth-21 2.0 1.0 Steareth-2 1.0 Cetearyl glucoside 2.0 Myristyl myristate 1.0 Behenyl alcohol 1.0 2.0 Stearyl alcohol 5.0 Cetearyl alcohol 3.0 2.0 1.0 Cetyl alcohol 1.0 Hydrogenated Coco Glycerides 1.0 1 Butyrospermum Parkii (Shea) butter 2.5 C12-15 alkyl benzoates 2.0 5.0 2.5 Butylene glycol dicaprylate / dicaprate 1.5 2.0 Caprylic / Capric triglycerides 1.0 1.5 3.5 Ethylhexyl cocoate 2.0 octyldodecanol 1.0 1.5 Paraffinum Liquidum 1.0 Cera Microcristaliina 1.8 Cyclomethicone 4.0 3.5 2.0 5.0 2.0 Dimethicone 2.0 1.5 Dicaprylyl ether 2.0 Dicarprylyl carbonates 2.0 3.0 3.5 N- (4- (2,4-dihydroxyphenyl) thiazol-2-yl) -isobutyramide 0.1 0.15 0.25 0.1 0.5

Polydecene 4

Ethylhexyl methoxycinnamate

Phenylbenzimidazoie Sulphonic Acid

Disodium Phenyl Dibenzimidazole Tetrasulfonate

Ubiquinone (Q10) aqueous fish egg extract solution from (e). (50% aqueous fish egg extract + 50% glycine solution)

Lipophilic fish egg extract after working up from (e).

biotin

Retinyl palmitate

Tocopheryl Acetate

Ascorbic acid

Trisodium EDTA

phenoxyethanol

Butylparaben

Ethylhexylglycerin

Alcohol denat.

Xanthan gum

Carbomer

polyacrylamides

glycerin

Butylene glycol

Additives (distarch phosphate, SiO ₂ , talc,

BHT aluminum stearate)

perfumes

Aqua

2.0 3.0 4.5 5.0 4.2 0.5 2.0 2.0 3.3 1.0 1.0 1.0 1.5 2.3 0.5 0.03 0.06 0.4 0.12 0.35 0.25 0.03 0.35 0.06 0.3 0.25 0.02 0.2 1.0 0.05 0.5 0.2 0.1 0.5 0.4 0.5 0.3 0.1 0.4 0.6 0.2 0.2 0.1 0.4 8.0 3.0 0.1 0.2 0.2 0.1 0.1 10 5.0 6.0 4.0 7.0 2.0 0.03 0.05 3.0 q.s. q.s. q.s. q.s. q.s. ad ad ad ad ad 100 100 100 100 100

Example number

PEG-100 stearate

Glyceryl stearate

Ceteareth-100

Sorbitan stearate

Polysorbate 60

Polysorbate 80

Sorbitan isostearates

Theobroma Grandiflorum Seed Butter

11 12 13 14 15 1.4 0.1 1.2 1.4 0.5 0.2 1.0 0.9 2 3.1 2.1 2.3 2.5 0.1 0.3 0.8 0.7 0.8 0.5 0.1 0.1 0.25 0.05 3.0 1.2 2.7

Butyrospermum Parkii (Shea) butter 2.5 3.5 1.9 Jojoba Esters 2.0 2.5 1.3 0.5 1.0 Beewax 1.0 0.2 0.8 1.6 2.0 Helianthus Annuus Seed Oil 0.5 0.1 Persea gratissima oil 0.7 0.3 0.5 Olea Europaea Fruit Oil 0.1 0.6 0.1 Cyclometh icone 3.6 0.1 0.1 1.2 Dimethicone 5.4 4.5 5.0 3.6 Squalane 3.0 1.9 Carbomer 0.2 0.4 0.15 Hydroxyethyl Acrylate / Sodium Acryloydimethyl Taurate Copolymer 1.7 0.1 1.0 2.0 0.1 Polymethyl methacrylates 0.5 0.6 0.1 Dimethicone cross polymer 0.6 0.3 0.25 pullulan 0.5 0.4 carrageenan 0.2 0.3 0.7 0.3 Caprylyl glycol 0.3 0.1 0.25 Methylpropanediol 1.3 glycerin 3.1 1.7 4.0 2.8 3.5 sorbitol 0.1 propanediol 2.0 1.9 Propylene glycol 0.1 0.1 0.2 0.3 Pentylene glycol 0.1 0.5 Butylene glycol 0.2 0.3 0.2 Tocopherol Acetate 0.5 0.2 0.45 0.35 ubiquinones 0.1 0.2 0.15 Retinyl palmitate 0.15 0.15 biotin 0.05 aqueous fish egg extract solution from (a). (50% aqueous fish egg extract + 50% glycine solution) 0.2 0.1 0.3 0.09 0.4 Lipophilic fish egg extract after working up from (b). 0.2 0.1 0.3 0.5 0.4 Disodium EDTA 0.1 0.1 0.1 0.1 0.1 Triethanolamine 0.1 0.1 0.1 0.1 0.1 phenoxyethanol 0.4 0.3 0.5 0.3 0.45 Ethylhexylglycerin 0.2 0.1 0.05 Titanium Dioxide 0.3 0.1 0.2

Tapioca Starch 0.05

talc 0.05 perfumes q.s. q.s. q.s. q.s. q.s. Aqua ad ad ad ad ad 100 100 100 100 100

Claims (21)

claims 1. Containing cosmetic or dermatological preparation I. an aqueous fish egg extract (I) characterized in that the aqueous fish egg extract (I) is obtainable by a1) suspending fish eggs in an extraction mixture containing an oil phase and an aqueous phase, b1) homogenizing the suspension mixture a1), and c1 ) the aqueous phase of the homogenate b1) is extracted to obtain the aqueous fish extract (I); and II. A lipophilic fish egg extract (II) characterized in that the lipophilic fish egg extract (II) is obtainable by a2) suspending fish eggs in an extraction mixture containing an oil phase and an aqueous phase, b2) homogenizing the suspension mixture a2), and c2) the oil phase of the homogenate b2) is extracted to obtain the lipophilic fish extract (II). 2. Cosmetic or dermatological preparation according to claim 1, characterized in that the fish eggs for the production of the aqueous fish egg extract (I) are selected from the fish eggs of the salmon, trout and sturgeon, fish eggs from sturgeons being preferred. 3. Cosmetic or dermatological preparation according to claim 2, characterized in that the fish eggs for producing the aqueous fish egg extract (I) are selected from the fish eggs of the white sturgeon and / or the Siberian sturgeon. 4. Cosmetic or dermatological preparation according to one of the preceding claims, characterized in that the fish eggs for producing the lipophilic fish egg extract (II) are selected from the fish eggs of the salmon, trout and sturgeon, fish eggs from sturgeons being preferred. 5. Cosmetic or dermatological preparation according to claim 4, characterized in that the fish eggs for producing the lipophilic fish egg extract (II) are selected from the fish eggs of the white sturgeon and / or the Siberian sturgeon. 6. Cosmetic or dermatological preparation according to one of the preceding claims, characterized in that the aqueous fish egg extract (I) and / or the lipophilic fish egg extract (II) are produced within 24 hours after the fish eggs have been removed. 7. Cosmetic or dermatological preparation according to one of the preceding claims, characterized in that for the production of the hydrophilic fish extract (I) contains the oil phase contained in the extraction mixture caprylic / capric triglycerides, the proportion of the oil caprylic / capric triglycerides in the oil phase Extraction mixture is preferably at least 90% by weight and particularly preferably at least 97% by weight, based on the total weight of the oil phase of the extraction mixture. 8. Cosmetic or dermatological preparation according to one of the preceding claims, characterized in that for the production of the lipophilic fish egg extract (II) contains the oil phase contained in the extraction mixture caprylic / capric triglycerides, the proportion of the oil caprylic / capric triglycerides in the oil phase of the Extraction mixture is preferably at least 90% by weight and particularly preferably at least 97% by weight, based on the total weight of the oil phase of the extraction mixture. 9. Cosmetic or dermatological preparation according to one of the preceding claims, characterized in that the aqueous phase for the preparation of the aqueous fish extract (I) and / or for the production of the lipophilic fish extract (II) 50 mM to 200 mM and 0.1 to 0.3% by weight of EDTA, based on the total weight of the respective aqueous phase of the extraction mixture for the preparation of the aqueous fish egg extract (I) and / or for the production of the lipophilic fish egg extract (II). 10. Cosmetic or dermatological preparation according to one of the preceding claims, characterized in that for the production of the aqueous fish egg extract (I) and / or for the production of the lipophilic fish egg extract (II) the weight fraction of the fish eggs in relation to the aqueous phase of the respective suspension mixture 1 : 2 to 2: 1, preferably 1: 1.2 to 1.2: 1. 11. Cosmetic or dermatological preparation according to one of the preceding claims, characterized in that for the production of the aqueous fish egg extract (I) and / or for the production of the lipophilic fish egg extract (II) the weight fraction of the fish eggs in relation to the oil phase of the respective suspension mixture 1 : 0.2 to 1: 0.4. 12. Cosmetic or dermatological preparation according to one of the preceding claims, characterized in that a mechanical digestion process is used for the production of the aqueous fish egg extract (I) and / or for the production of the lipophilic fish egg extract (II) for the homogenization of the fish eggs. 13. Cosmetic or dermatological preparation according to claim 12, characterized in that for the production of the aqueous fish egg extract (I) and / or for the production of the lipophilic fish egg extract (II) for the homogenization, a method is applied under the application of mechanical pressure. 14. Cosmetic or dermatological preparation according to one of the preceding claims, characterized in that the extraction of the aqueous phase for the preparation of the aqueous fish extract (I) and / or the extraction of the oil phase for the production of the lipophilic fish extract (II) from the homogenates of suspension mixture is carried out by centrifugation with subsequent phase separation. 15. Cosmetic or dermatological preparation according to one of the preceding claims, characterized in that the aqueous fish egg extract (I) is characterized in that it contains DNA components in a weight fraction of 0.02 to 0.1% by weight, proteins in a weight fraction from 5 to 15% by weight and carbohydrates in a proportion by weight of 0.5 to 1% by weight, based on the total weight of the aqueous fish extract (I). 16. Cosmetic or dermatological preparation according to one of the preceding claims, characterized in that the aqueous fish egg extract (I) in a total proportion of 0.0001 to 10% by weight, preferably 0.05 to 5% by weight and in particular 0, 1 to 2 wt .-%, based on the total weight of the cosmetic or dermatological preparation, is included. 17. Cosmetic or dermatological preparation according to one of the preceding claims, characterized in that the aqueous fish egg extract (I) before incorporation into the cosmetic or dermatological preparation in a weight ratio of 1: 0.5 to 1: 1.5 with an aqueous glycine solution containing 1 up to 2% by weight of glycine, based on the total weight of the aqueous glycine solution. 18. Cosmetic or dermatological preparation according to one of the preceding claims, characterized in that the weight fraction of monounsaturated fatty acids in the lipophilic fish egg extract (II) 12 to 25 wt .-%, in particular 15 to 20 wt .-% based on the total weight of all im lipophilic fish egg extract (II) contains fatty acids. 19. Cosmetic or dermatological preparation according to one of the preceding claims, characterized in that the lipophilic fish egg extract (II) in a total proportion of 0.001 to 10% by weight, preferably 0.02 to 5% by weight, based on the total weight of the cosmetic or dermatological preparation. 20. Cosmetic or dermatological preparation according to one of the preceding claims, characterized in that at least one alkyl amide thiazole is contained. 21. Use of a cosmetic preparation according to one of claims 1 to 20, for plumping up the skin and / or for increasing the storage of triglycerides in adipocytes.